Results 161 to 170 of about 22,470,738 (286)

Copy number variation analysis of cerebrospinal fluid metagenomic next‐generation sequencing data in assisting the diagnosis of pediatric brain tumors

open access: yes
Pediatric Investigation, EarlyView.
Changhong Ren   +7 more
wiley   +1 more source

Review on enhancing clinical decision support system using machine learning

open access: yesCAAI Transactions on Intelligence Technology, EarlyView.
Abstract Clinical decision‐making is a complex patient‐centred process. For an informed clinical decision, the input data is very thorough ranging from detailed family history, environmental history, social history, health‐risk assessments, and prior relevant medical cases.
Anum Masood   +4 more
wiley   +1 more source

Breast implant-associated diffuse large cell B-cell lymphoma (BIA-DLBCL) - a case report and a treatment algorithm. [PDF]

open access: yesJPRAS Open
Borgolte MB   +6 more
europepmc   +1 more source

Advances in γδ T Cells: Cutaneous Biology and Therapeutic Potential for Skin Neoplasms

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT γδ T cells represent an increasingly important subset of T lymphocytes in the immune response to cancer and as a platform for novel immunotherapies. The aim of this review is to synthesize recent insights into the biology and advances in therapeutic applications of γδ T cells in cutaneous malignancies, especially melanoma, within a framework ...
Simo Du   +9 more
wiley   +1 more source

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend   +16 more
wiley   +1 more source

LTB‐TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma

open access: yesBritish Journal of Haematology, EarlyView.
LTB‐TREAT is a validated international prognostic model that identifies three groups of patients with distinct rates of time to treatment (TTT) in low tumour burden follicular lymphoma. The low‐risk group has a prolonged TTT with WW. The high‐risk group has early progression in whom treatment at diagnosis can be considered. Summary Watchful waiting (WW)
Luani Barge   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy